u87 mg red fluc cells  (Revvity)

Journal: Frontiers in Pharmacology

Article Title: Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth

doi: 10.3389/fphar.2021.746470

Figure Lengend Snippet: Morphological growth and luciferase activity in U87MG cells. Representative images of U87MG cells at 3 (A) , 36 (B) , and 72 (C) hours at 20x magnification after taking out of Cryofrizide. A luciferase receptor gene was used to tag the U87MG cells. Steady growth and attenuation of the morphological pattern of U87MG cells present at 36 and 72 h. (D) Detection of luciferase activity expressed in luciferase units (LFU) in U87MG and hRPE cells. Results are the average of three independent experiments.

Article Snippet: The human cell line U87 MG-Red-Flug (U87MG) containing a luciferase-expressing gene was purchased from PerkinElmer (Waltham, MA).

Techniques: Luciferase, Activity Assay

Journal: Frontiers in Pharmacology

Article Title: Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth

doi: 10.3389/fphar.2021.746470

Figure Lengend Snippet: (A) Experimental design, showing bregma level and site of tumor cell implantation in anesthetized athymic nude female mice, secured in a stereotactic head frame. (B) Timeline showing GBM implantation, imaging, and treatments. Mice underwent stereotactic implantation of the luciferase-modified U87MG cells on day 0 and were monitored during a 30-day survival period. Treatment was started on day 13 post-implantation. In vivo bioluminescent imaging was performed on days 13, 20, and 30 post-implantation. On day 30, mice were sacrificed, and ex vivo MRI was conducted on perfused brains.

Article Snippet: The human cell line U87 MG-Red-Flug (U87MG) containing a luciferase-expressing gene was purchased from PerkinElmer (Waltham, MA).

Techniques: Imaging, Luciferase, Modification, In Vivo, Ex Vivo

Journal: Frontiers in Pharmacology

Article Title: Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth

doi: 10.3389/fphar.2021.746470

Figure Lengend Snippet: Quantification of bioluminescent signals from tumors. Radiance (Radiance × 10 6 ) values from regions of interest in mice from all groups were averaged and compared on days 13, 20, and 30 following intracranial implantation of U87-Luc cells. Tumor-bearing mice treated with (A) LAU-0901, Avastin, LAU-0901 + Avastin and (B) ELV, ELV + LAU-0901, and ELV + Avastin were observed have significantly reduced tumorigenesis when compared to vehicle-treated mice. All values are mean ± SEM ( n = 5–7), * p < 0.05.

Article Snippet: The human cell line U87 MG-Red-Flug (U87MG) containing a luciferase-expressing gene was purchased from PerkinElmer (Waltham, MA).

Techniques:

Journal: Molecular cancer therapeutics

Article Title: Sprague Dawley Rag2 null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts

doi: 10.1158/1535-7163.MCT-18-0156

Figure Lengend Snippet: Subcutaneous growth of human glioblastoma U87MG cells in the SDR rat. 1×106 U87MG cells resuspended in Geltrex were injected subcutaneously into SDR rats. (A) Tumor growth in two different SDR animals with images of their excised tumors. (B) Tumor volume (mm3) over time. Each line represents tumor growth in an individual rat. (C) Immunohistochemistry of anti human-mitochondria in tumor tissue and rat tissue. Brown staining demonstrates peri-nuclear localization of human-mitochondria protein in a tumor section, with (right) and without (left) hematoxylin counterstain. 40x magnification. The antibody for human mitochondria protein does not show staining in tissue from a rat that was not injected with human cells (negative control). Right panel with hematoxylin counterstain; 40× magnification; Scale bar = 100μm.

Article Snippet: Human glioblastoma cell line U87MG Red FLuc (Perkin Elmer, {"type":"entrez-nucleotide","attrs":{"text":"BW124577","term_id":"24480976","term_text":"BW124577"}} BW124577 ) was a gift from Dr. Bjoern Bauer at the University of Kentucky, human NSCLC cell line H358 (bronchioalveolar carcinoma, mutant KRAS) was a gift from Dr. Goutham Narla at the Case Comprehensive Cancer Center, Cleveland, Ohio, human ovarian carcinoma cell line OV81 obtained from high grade serous ovarian cancer patient’s PDX tumor and human endometriod cancer cell line OV185 obtained from a recurrent endometriod patient’s PDX tumor was a gift from Dr. Analisa DiFeo at the Case Comprehensive Cancer Center, Cleveland, Ohio.

Techniques: Injection, Immunohistochemistry, Staining, Negative Control